Obviously, the first question is how Amazon and Ginkgo Bioworks--two inherently different companies--are at all similar?
"Ginkgo, just like Amazon, we get better with every new cell program we do because our scale goes up, our costs fall and we can offer a better platform for customers," Kelly said.
But, aside from that, Ginkgo is a newly public company after completing a SPAC with Soaring Eagle Acquisition Corp.
The company will trade on the New York Stock Exchange under the ticker symbol DNA.
"For nearly two decades, my co-founders and I have been on a mission to make programming cells as easy as programming computers," said Jason Kelly, CEO and co-founder at Ginkgo in a press release. "Today marks an important milestone not only for the team at Ginkgo, but for synthetic biology as a whole, and I am thrilled to work with our team, partners, and investors as we continue scaling our platform to solve even bigger problems with biology."
But what does he mean by making cells as easily programmed as computers?
Kelly answers that question and more in the video above.